Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Arlen

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|July 25, 2016
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancerMuhammad S Beg, Nilofer S Azad, Sandip P Patel, et al.
Frontiers in Immunology|January 23, 2018
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human CarcinomasMassimo Fantini, Justin M David, Olga Saric, et al.
Journal of Clinical Pharmacology|May 20, 2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancerWilliam L Dahut, Jeanny B Aragon-Ching, Sukyung Woo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantRobert J Lechleider, Philip M Arlen, Kwong-Yok Tsang, et al.
The Prostate|September 21, 2002
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancerJames Gulley, Alice P Chen, William Dahut, et al.
Cancer Immunology, Immunotherapy : CII|October 27, 2010
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccinationMatteo Vergati, Vittore Cereda, Ravi A Madan, et al.
Cancer Immunology, Immunotherapy : CII|December 12, 2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinomaMarijo Bilusic, Christopher R Heery, Philip M Arlen, et al.
Current Pharmaceutical Design|February 4, 2006
TRICOM vector based cancer vaccinesCharlie T Garnett, John W Greiner, Kwong-Yok Tsang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyWilfred D Stein, James L Gulley, Jeff Schlom, et al.
Cancer Immunology, Immunotherapy : CII|June 5, 2009
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapyVittore Cereda, Diane J Poole, Claudia Palena, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|July 25, 2016
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancerMuhammad S Beg, Nilofer S Azad, Sandip P Patel, et al.
Frontiers in Immunology|January 23, 2018
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human CarcinomasMassimo Fantini, Justin M David, Olga Saric, et al.
Journal of Clinical Pharmacology|May 20, 2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancerWilliam L Dahut, Jeanny B Aragon-Ching, Sukyung Woo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantRobert J Lechleider, Philip M Arlen, Kwong-Yok Tsang, et al.
The Prostate|September 21, 2002
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancerJames Gulley, Alice P Chen, William Dahut, et al.
Cancer Immunology, Immunotherapy : CII|October 27, 2010
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccinationMatteo Vergati, Vittore Cereda, Ravi A Madan, et al.
Cancer Immunology, Immunotherapy : CII|December 12, 2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinomaMarijo Bilusic, Christopher R Heery, Philip M Arlen, et al.
Current Pharmaceutical Design|February 4, 2006
TRICOM vector based cancer vaccinesCharlie T Garnett, John W Greiner, Kwong-Yok Tsang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyWilfred D Stein, James L Gulley, Jeff Schlom, et al.
Cancer Immunology, Immunotherapy : CII|June 5, 2009
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapyVittore Cereda, Diane J Poole, Claudia Palena, et al.
Pageof 18